Policy and perspectives

Maddy Dawson and Yasmina Zegaoui summarise the key changes that will affect the assessment and pricing of medicines in Germany and the impact these changes will have on the pharmaceutical industry

Yasmina Zegaoui outlines the key changes

Jake James and Eleanor Butler take a look at the key highlights

Maddy Dawson takes a look at how the draft measures, if implemented, will affect the pharmaceutical industry

Maddy Dawson and Eleanor Butler provide a round up of the key topics discussed during the Supporting Pharmaceutical Innovation in Europe webinar

Nasos Kipentzoglou presents new research at ISPOR Europe 2021 looking at the current processes for the evaluation of digital therapeutics (DTx), to ensure they meet the requirements of healthcare systems and ultimately, benefit patients. (POSB295)

Yasmina Zegaoui and Eleanor Butler present recent research at ISPOR Europe reviewing cross-country collaboration models with a focus on health technology assessment. (POSA326)

An overview of the recent European policy updates and the implications they may have for the launch of ATMPs in Europe

Yasmina Zegaoui looks at how this managed entry agreement initiative can enable the reimbursement of a much-needed therapy for patients

Yasmina Zegaoui and Nasos Kipentzoglou report on some of the key topics from the two-day event